Tags

Type your tag names separated by a space and hit enter

[ANMCO Position paper: Vericiguat use in heart failure: from evidence to place in therapy].
G Ital Cardiol (Rome). 2023 Apr; 24(4):323-331.GI

Abstract

In the growing therapeutic armamentarium for heart failure management, vericiguat represents an innovative therapeutic option. The biological target of this drug is different from that of other drugs for heart failure. Indeed, vericiguat does not inhibit neurohormonal systems overactivated in heart failure or sodium-glucose cotransporter 2 but stimulates the biological pathway of nitric oxide and cyclic guanosine monophosphate, which is impaired in patients with heart failure. Vericiguat has recently been approved by international and national regulatory authorities for the treatment of patients with heart failure and reduced ejection fraction who are symptomatic despite optimal medical therapy and have worsening heart failure. This ANMCO position paper summarizes key aspects of vericiguat mechanism of action and provides a review of available clinical evidence. Furthermore, this document reports use indications based on international guideline recommendations and local regulatory authority approval at the time of writing.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Di Fusco SA
U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri - ASL Roma 1, Roma.
Alonzo A
U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri - ASL Roma 1, Roma.
Aimo A
Scuola Superiore Sant'Anna, Pisa.
Matteucci A
U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri - ASL Roma 1, Roma.
Intravaia RCM
Cardiologia 4-Diagnostica e Riabilitativa, Dipartimento Cardiotoracovascolare "A. De Gasperis", ASST Grande Ospedale Metropolitano Niguarda, Milano.
Aquilani S
U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri - ASL Roma 1, Roma.
Cipriani M
U.O. Cardiologia, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione-ISMETT, Palermo.
De Luca L
U.O.C. Cardiologia, Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliera San Camillo Forlanini, Roma.
Navazio A
S.O.C. Cardiologia Ospedaliera, Presidio Ospedaliero Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia - IRCCS, Reggio Emilia.
Valente S
Dipartimento Cardio-Toracico, A.O.U. Senese, Ospedale Santa Maria alle Scotte, Siena.
Gulizia MM
U.O.C. Cardiologia, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione "Garibaldi", Catania.
Gabrielli D
U.O.C. Cardiologia, Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliera San Camillo Forlanini, Roma - Fondazione per il Tuo cuore - Heart Care Foundation, Firenze.
Oliva F
Cardiologia 1-Emodinamica, Dipartimento Cardiotoracovascolare "A. De Gasperis", ASST Grande Ospedale Metropolitano Niguarda, Milano.
Colivicchi F
U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri - ASL Roma 1, Roma.

MeSH

HumansHeart FailureHeterocyclic Compounds, 2-RingPyrimidinesVentricular Dysfunction, LeftStroke Volume

Pub Type(s)

Review
English Abstract
Journal Article
Consensus Development Conference

Language

ita

PubMed ID

36971177

Citation

Di Fusco, Stefania Angela, et al. "[ANMCO Position Paper: Vericiguat Use in Heart Failure: From Evidence to Place in Therapy]." Giornale Italiano Di Cardiologia (2006), vol. 24, no. 4, 2023, pp. 323-331.
Di Fusco SA, Alonzo A, Aimo A, et al. [ANMCO Position paper: Vericiguat use in heart failure: from evidence to place in therapy]. G Ital Cardiol (Rome). 2023;24(4):323-331.
Di Fusco, S. A., Alonzo, A., Aimo, A., Matteucci, A., Intravaia, R. C. M., Aquilani, S., Cipriani, M., De Luca, L., Navazio, A., Valente, S., Gulizia, M. M., Gabrielli, D., Oliva, F., & Colivicchi, F. (2023). [ANMCO Position paper: Vericiguat use in heart failure: from evidence to place in therapy]. Giornale Italiano Di Cardiologia (2006), 24(4), 323-331. https://doi.org/10.1714/4004.39824
Di Fusco SA, et al. [ANMCO Position Paper: Vericiguat Use in Heart Failure: From Evidence to Place in Therapy]. G Ital Cardiol (Rome). 2023;24(4):323-331. PubMed PMID: 36971177.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [ANMCO Position paper: Vericiguat use in heart failure: from evidence to place in therapy]. AU - Di Fusco,Stefania Angela, AU - Alonzo,Alessandro, AU - Aimo,Alberto, AU - Matteucci,Andrea, AU - Intravaia,Rita Cristina Myriam, AU - Aquilani,Stefano, AU - Cipriani,Manlio, AU - De Luca,Leonardo, AU - Navazio,Alessandro, AU - Valente,Serafina, AU - Gulizia,Michele Massimo, AU - Gabrielli,Domenico, AU - Oliva,Fabrizio, AU - Colivicchi,Furio, PY - 2023/3/28/medline PY - 2023/3/27/entrez PY - 2023/3/28/pubmed SP - 323 EP - 331 JF - Giornale italiano di cardiologia (2006) JO - G Ital Cardiol (Rome) VL - 24 IS - 4 N2 - In the growing therapeutic armamentarium for heart failure management, vericiguat represents an innovative therapeutic option. The biological target of this drug is different from that of other drugs for heart failure. Indeed, vericiguat does not inhibit neurohormonal systems overactivated in heart failure or sodium-glucose cotransporter 2 but stimulates the biological pathway of nitric oxide and cyclic guanosine monophosphate, which is impaired in patients with heart failure. Vericiguat has recently been approved by international and national regulatory authorities for the treatment of patients with heart failure and reduced ejection fraction who are symptomatic despite optimal medical therapy and have worsening heart failure. This ANMCO position paper summarizes key aspects of vericiguat mechanism of action and provides a review of available clinical evidence. Furthermore, this document reports use indications based on international guideline recommendations and local regulatory authority approval at the time of writing. SN - 1972-6481 UR - https://www.unboundmedicine.com/medline/citation/36971177/ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓4]

Related Citations

    More

    Others Viewed